JF Yale, TR Valiquett, MN Ghazzi, JK Owens- … - Annals of internal medicine, 2001 - Am Coll Physicians The Effect of a Thiazolidinedione Drug, Troglitazone, on Glycemia in ...
Patients with Type 2 Diabetes Mellitus Poorly Controlled with ... A
Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Cited by 76 - Related articles - BL Direct - All 4 versions
V Panikar, HB Chandalia, S Joshi, A Fafadia, … - International Journal of Diabetes in Developing …, 2003 - ijddc.com Type 2 diabetes mellitus is characterized by the presence of insulin resistance
with concomitant or eventual beta cell dysfunction. Resistance to
insulin-stimulated glucose uptake is present in most patients with this ... Cited by 8 - Related articles - Cached - BL Direct - All 5 versions
LA Gavin, MD, FACP, FRCP, J Barth, RN, D … - Endocrine Practice, 2000 - AACE (9.3%) is substantially above this minimal target goal (1-3). Recent studies
support the ADA standards and have proved that “tighter” control of diabetes
can significantly reduce the associated complications (4,5). Therefore, ... Cited by 19 - Related articles - BL Direct - All 2 versions
D Einhorn, M Rendell, J Rosenzweig, JW … - Clinical Therapeutics, 2000 - Elsevier Methods: This was a 16-week, double-blind study with the option of enrollment in
a separate open-ended, open-label study. It included patients with poorly
controlled diabetes mellitus (glycated hemoglobin [HbA 1c ] ≥8.0%, ... Cited by 71 - Related articles - BL Direct - All 3 versions
GE Dailey, MA Noor, JS Park, S Bruce, FT … - The American journal of medicine, 2004 - Elsevier Following an open-label, lead-in phase to optimize the dosing of
glyburide/metformin tablets, 365 patients randomly received additive therapy
comprising rosiglitazone (4 mg once daily) or placebo for 24 weeks. Based ... Cited by 63 - Related articles - All 9 versions
DSH Bell, F Ovalle - Endocrine Practice, 2002 - AACE Before 1995 in the United States, only insulin and sul- fonylureas were
available for treatment of type 2 diabetes. When sulfonylureas failed to provide
glycemic control, insulin either was added to or replaced sulfonylurea ... Cited by 49 - Related articles - BL Direct - All 2 versions
- ►diabetesjournals.org [PDF] ES Horton, F Whitehouse, MN Ghazzi, TC … - Diabetes Care, 1998 - Am Diabetes Assoc Type 2 diabetes is a chronic and pro- g ressive disease that affects more than
16 million people in the US, half of whom do not even know they have the disease
(1,2). The cost of tre ating diabetes and its long-term complications ( re ... Cited by 99 - Related articles - BL Direct - All 5 versions
- ►diabetesjournals.org [PDF] P Raskin, L Jovanovic, S Berger, S Schwartz, … - Diabetes Care, 2000 - Am Diabetes Assoc From the University of Texas Southwest Medical Center (PR), Dallas, Texas; the
Sansum Medical Research Institute (LJ), La Jolla, California; the Chicago Center
for Clinical Research (SB), Chicago, Illinois; the Dia- betes and Glandular ... Cited by 43 - Related articles - BL Direct - All 5 versions
MS Kipnes, A Krosnick, MS Rendell, JW Egan … - The American journal of medicine, 2001 - Elsevier RESULTS: Patients receiving pioglitazone + sulfonylurea had significant (P
<0.05) decreases from baseline in HbA 1C and fasting plasma glucose levels
compared with patients treated with placebo + sulfonylurea. As compared ... Cited by 235 - Related articles - BL Direct - All 8 versions
D Einhorn, M Rendell, J Rosenzweig, JW … - Clinical therapeutics, 2000 - ncbi.nlm.nih.gov BACKGROUND: Their complimentary mechanisms of action suggest that a combination
of pioglitazone hydrochloride and metformin may have clinically beneficial
effects in the treatment of patients with type 2 diabetes. OBJECTIVE: This ... Cited by 169 - Related articles
